Background
==========

*NMNAT2*(rs2022013 located at intron 1) was identified as a SLE risk locus in a European-derived population in a genome-wide association study (GWAS). *NMNAT2*(nicotinamide mononucleotide adenylyltransferase 2) is expressed mainly in the brain, regulating energy metabolism. Proximal to the SLE-associated *NMNAT2*variant is *SMG7*, encoding a component of the mRNA quality control pathway that regulates spliceosomal machinery such as Sm and snRNP via alternative splicing. We fine mapped the *NMNAT2/SMG7*region in multiple ancestries and explored functional consequences of the identified variants.

Materials and Methods
=====================

We genotyped/imputed 313 SNPs covering an \~550 kb *NMNAT2/SMG7*region in 15,424 case-control subjects from European-Americans (EA), African Americans, Asians and Amerindian/Hispanics, assessed SNPs for association with SLE using a logistic regression model adjusted for sex and ancestry, and used haplotype-based conditional testing to distinguish independent associations. Quantitative real-time PCR and luciferase reporter assays were used to examine allelic differences in *SMG7*expression and transcription activity. PBMCs from SLE patients (*n*= 13) were cultured with or without siRNA targeting *SMG7, GAPDH*(positive control) or siRNA with a nontargeting sequence (NC, negative control), and culture supernatants were measured by ELISA for levels of antinuclear antibody (ANA) and cytokines/chemokines.

Results
=======

We confirmed association at rs2022013 and identified two independent signals in EA only: intron 1 of *NMNAT2*tagged by rs12146097 (*P*= 1.5 × 10^-10^, OR = 1.38); and multiple *SMG7*SNPs tagged by rs2275675 (*P*= 5.7 × 10^-8^, OR = 1.22). Expression quantitative trait locus data showed SLE-risk alleles of *NMNAT2/SMG7*variants consistently associated with decreased mRNAs of *SMG7*, but not *NMNAT2*, in cell lines, suggesting *SMG7*is a more likely risk gene for SLE. The rs2275675 risk allele was associated with decreased *SMG7*mRNAs dose dependently in PBMCs of 86 SLE patients and 119 controls (*P*= 0.001 and 6.84 × 10^-8^, respectively), and reduced transcription activity in two transfected cell lines (*P*≤ 0.004). *SMG7*mRNA levels in PBMCs correlated inversely with ANA titers in 68 SLE patients (*P*= 0.0089, *r*= -0.31). Compared with culture supernatants of SLE PBMCs treated with NC-siRNA, those treated with *SMG7-*siRNA showed increased ANA (*P*\< 0.0001) and CCL19 (*P*= 0.0002; a ligand for CCR7 promoting movement/ interaction of B-Th cells and antibody production).

Conclusions
===========

We confirmed the previous GWAS *NMNAT2*association and identified independent *SMG7*association with SLE in an EA population. The SLE-risk alleles are dose-dependently associated with decreased *SMG7*mRNAs, and *SMG7*reduction increases ANA and CCL19 production in PBMC cultures of SLE patients, suggesting that dysfunction in mRNA surveillance conferred by SLE-associated *SMG7*variants contributes to SLE manifestations.
